INDIA CARDIOVASCULAR ULTRASOUND MARKET FORECAST 2026-2034

India’s policy environment is increasingly aligned with cardiovascular disease control and diagnostic capacity building. The government’s Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), the world’s largest government-funded health assurance scheme, provides health coverage of up to ₹5 lakh per family per year for secondary and tertiary care, including cardiac procedures and diagnostics, to over 12 crore poor and vulnerable families, as confirmed by the National Health Authority of India.

Cardiac conditions represent a disproportionately high share of PM-JAY expenditure. According to research, while cardiac-related claims accounted for roughly 5% of all PM-JAY claims between 2018 and 2020, they consumed approximately 26% of total scheme expenditure, reflecting the clinical weight of heart disease in India’s public health system and the government’s commitment to funding cardiac care access.

In September 2024, the Union Cabinet further expanded PM-JAY coverage to all senior citizens above the age of 70, regardless of socioeconomic status, extending cardiac care access to an age group at disproportionately high cardiovascular risk. These policy actions are creating a more structured and government-supported demand environment for cardiac ultrasound systems across public hospitals nationwide.

Beyond the public sector, India’s private multispecialty hospital segment is a strong and accelerating demand driver for advanced cardiovascular imaging. Hospital chains across Tier 1 and major Tier 2 cities are actively investing in high-end cardiac ultrasound systems, including 3D and 4D platforms and AI-assisted echocardiography, to attract cardiac patients and establish centers of cardiac excellence.

At the same time, the government’s push to improve healthcare access in rural and semi-urban regions is driving demand for portable and point-of-care cardiac ultrasound systems that can function in facilities with limited specialist support. These intersecting forces, high disease burden, expanding government insurance coverage, growing private sector investment, and rural healthcare outreach, give the India cardiovascular ultrasound market a growth trajectory that is among the steepest in Asia-Pacific over the forecast period.

The India cardiovascular ultrasound market is segmented by device display, technology, application, type, and end-user. The end-user segment is further categorized into hospitals, diagnostic centers, ambulatory care centers, and other end-users.

Hospitals hold the dominant share within the end-user segment of the India cardiovascular ultrasound market, and their commanding position is rooted in both clinical and structural realities of India’s healthcare landscape. Hospitals, both public and private, are the primary sites for cardiac diagnosis and treatment in India. They house the cardiologist workforce, the imaging infrastructure, and the procedural capacity necessary to deploy and fully utilize cardiovascular ultrasound systems, including the full range of transthoracic echocardiogram, transesophageal echocardiogram, and stress echocardiogram procedures.

Public hospitals, particularly those at the district and tertiary levels, are major recipients of government-funded medical equipment under national health programs, making them important volume buyers for cardiac ultrasound systems. Meanwhile, India’s rapidly expanding private multispecialty hospital sector, led by national chains and regional tertiary centers, consistently invests in premium cardiovascular imaging platforms to support high-acuity cardiac programs and attract specialized cardiology talent.

The Ayushman Bharat framework further amplifies hospital-based demand by expanding the insured patient base, making cardiac diagnostic procedures financially accessible to a significantly wider population. For vendors, hospitals represent the most predictable, high-volume, and relationship-driven end-user segment in the India cardiovascular imaging market, one where procurement decisions, replacement cycles, and service contract structures are well-established and commercially favorable.

Some of the top players operating in the India cardiovascular ultrasound market include Samsung Medison Co Ltd, GE HealthCare, Koninklijke Philips NV, Siemens Healthineers AG, Mindray Medical International Limited, etc.

Samsung Medison Co Ltd is a Seoul, South Korea-headquartered medical imaging company and an affiliate of Samsung Electronics, with a growing and strategically important presence in the India cardiovascular ultrasound market. Founded in 1985, Samsung Medison specializes in diagnostic ultrasound systems across multiple clinical disciplines, including cardiovascular imaging, general imaging, and women’s health. Its cardiac ultrasound portfolio spans premium console-based systems to compact point-of-care platforms, with a strong focus on AI integration and workflow automation.

Its most recent major product development is the Samsung R20, an AI-enabled ultrasound system powered by Samsung’s Advanced Imaging Engine. The platform integrates advanced hardware with sophisticated software beamforming to deliver enhanced image clarity and diagnostic precision. Unveiled at RSNA 2025 in Chicago, the R20 offers more than a dozen AI-powered tools for real-time exam guidance, diagnostic assistance, workflow automation, and automated measurements.